China NMPA approves Redemplo (plozasiran) for familial chylomicronemia syndrome; Sanofi to commercialize

Arrowhead Pharmaceuticals/Plozasiran (Redemplo)

China's National Medical Products Administration (NMPA) approved REDEMPLO for FCS, with Sanofi signing a commercial agreement to market it in Greater China, extending Arrowhead's geographic reach.